Subcutaneous versus intravenous double-dose infliximab for dose intensification in young adults with Crohn's disease: a prospective comparative study. (PubMed, Dig Liver Dis) - Oct 23, 2026 - "These exploratory findings suggest that subcutaneous infliximab may provide a more stable pharmacokinetic profile, while no statistically significant between-group difference in mucosal healing was observed."
Journal • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease
|
|
Eun Sil Kim; Mi Jin Kim; Tae Jong Jeong; Yiyoung Kwon; Yon Ho Choe; Yoon Zi Kim
|